Now livetag icon
2026 State of Ecommerce: Own the AI Shopper Journey.Download Reportbanner icon
Vor Bio

August 2026

Vor Bio Market Share Analysis for August 2026

[...]Read More... from Careers
Year Founded2015
Employees51 - 200
Annual Revenue$25M - $50M
vorbio.com
Vor Bio
Vor Bio (including company regionals)
  • vorbio.com
    vorbio.com
See more website traffic and engagement information

Vor Bio Revenue up to August 2026 is 25M - 50M

revenue generated by Vor Bio top domains

Vor Bio top domains revenue over 3 years

Revenue for Vor Bio top domains


Total visits to Vor Bio's top domains

Understand Vor Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in Vor Bio's top domains

Analyze Vor Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on Vor Bio's top domains

See how Vor Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by Vor Bio

These are the website technologies, by industry, used by Vor Bio top domains

Widget (8)

Twemoji

Twemoji

Social (6)

Instagram

Instagram

Mobile (3)

Meta Viewport

Meta Viewport

Advertising (2)

DoubleClick

DoubleClick

More Technologies

13

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Vor Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVor Bio, Inc. is developing telitacicept on Sep 1st '26.Vor Bio is progressing its lead candidate, telitacicept - a novel dual-target fusion protein advancing through Phase 3 clinical development - aimed at addressing serious autoantibody-driven conditions globally.
NewsVor Bio, Inc. hired David Zaccardelli as Board of Directors on Jul 7th '26.Vor Bio appoints David Zaccardelli to Board of Directors.

See all Vor Bio signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.